References
- Boeckxstaens G, El-Serag HB, Smout AJ, et al. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63:1185–1193.
- El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880.
- Patrick L. Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. Altern Med Rev. 2011;16:116–133.
- Bytzer P. What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment? Clin Gastroenterol Hepatol. 2009;7:816–822.
- Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309.
- Stanghellini V, Armstrong D, Monnikes H, et al. Systematic review: do we need a new gastro-oesophageal Reflux Disease Questionnaire? Digestion. 2007;75:3–16.
- Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:52–57.
- Armstrong D, Bardhan KD, Fass R, et al. Evaluating GERD symptoms: ReQuest™. Digestion. 2007;75, Suppl. 1:1–100.
- Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59:714–721.
- Shaw M, Dent J, Beebe T, et al. The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes. 2008;6:31.
- Reimer C, Lodrup AB, Smith G, et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43:899–909.
- Bardhan KD, Berghofer P. Look-but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment. Digestion. 2007;75:87–100.
- Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.
- Hays RD, Revicki DA, Reliability and validity, including responsiveness. In: Fayers PM, Hays RD, editors. Assessing quality of life in clinical trials. New York: Oxford University Press; 2005. p. 25–39.
- Fass R, Bothe G. Pantoprazole improves symptoms of gastroesophageal reflux disease beyond heartburn. Gut. 2007;56:A215.
- Fass R, Bothe G. The effect of pantoprazole versus placebo on gastroesophageal reflux disease (GERD) related symptoms other than heartburn. Gastrointest Endosc. 2008;67:AB196.
- Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27:S178–S189.
- Norman GR, Sridhar FG, Guyatt GH, et al. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39:1039–1047.
- Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861–873.
- Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
- Vakil N, Bjorck K, Denison H, et al. Validation of the Reflux Symptom Questionnaire electronic Diary in partial responders to proton pump inhibitor therapy. Clin Transl Gastroenterol. 2012;3:e7.
- Ryden A, Denison H, Karlsson M, et al. Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. Scand J Gastroenterol. 2013;48:1018–1026.
- Food Drug Administration (FDA). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74:65132–65133.